Cell Therapies in Bladder Cancer Management

Int J Mol Sci. 2021 Mar 10;22(6):2818. doi: 10.3390/ijms22062818.


Currently, bladder cancer (BC) represents a challenging problem in the field of Oncology. The high incidence, prevalence, and progression of BC have led to the exploration of new avenues in its management, in particular in advanced metastatic stages. The recent inclusion of immune checkpoint blockade inhibitors as a therapeutic option for BC represents an unprecedented advance in BC management. However, although some patients show durable responses, the fraction of patients showing benefit is still limited. Notwithstanding, cell-based therapies, initially developed for the management of hematological cancers by infusing immune or trained immune cells or after the engineering of chimeric antigen receptor (CAR) expressing cells, are promising tools to control, or even cure, solid tumors. In this review, we summarize recent cell-based immunotherapy studies, with a special focus on BC.

Keywords: CAR-T cells; bladder cancer; cell therapy; chimeric antigen receptor; immunotherapy.

Publication types

  • Review

MeSH terms

  • Cell- and Tissue-Based Therapy*
  • Humans
  • Immunotherapy, Adoptive*
  • Receptors, Chimeric Antigen / therapeutic use*
  • Urinary Bladder Neoplasms / pathology
  • Urinary Bladder Neoplasms / therapy*


  • Receptors, Chimeric Antigen